Skip to NavigationSkip to content

European Commission authorises Janssen’s anti-depressant Spravato

Published on 23/12/19 at 12:49pm

The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that has been treatment resistant (TRD).

Bernardo Soares, Medical Director at Janssen UK, said: “We are proud to be introducing this innovative treatment option, which we hope will help to address a significant unmet need.”

The authorisation was based on clinical trial data from a programme treating patients with TRD, including over 1,600 that were treated with Spravato. The five Phase 3 trials included three short-term studies, one randomised withdrawal and maintenance of effect study, and one long-term safety study.

The one-month flexible dosing study in adults under 65 years of age demonstrated statistically significant reductions in depressive symptoms at 28 days for esketamine nasal spray and oral antidepressant compared to oral antidepressant and placebo nasal spray. Approximately 70 percent of esketamine nasal spray-treated patients responded to treatment, with a 50 percent symptom reduction. Also, approximately half of all esketamine nasal spray-treated patients achieved remission at the end of the 4-week study.

Professor Allan Young, Chair of Mood Disorders and Director of the Centre for Affective Disorders at King’s College London, said: “This new treatment represents an exciting new therapeutic option for a common, debilitating and difficult to treat condition. I believe both clinicians and patients will welcome this treatment option for this often-devastating illness.”

Major depressive disorder is a severe and chronic mood disorder. Treatment-resistant depression (TRD) is defined as an inadequate response to two or more currently available treatments with antidepressants in a single, current episode of moderate-to-severe depression. A third of people who suffer from MDD do not respond to treatment and are considered to have TRD.

Conor Kavanagh

Comments

I’ve been searching for some decent stuff on the subject and haven't had any luck up until this point, You just got a new biggest fan!.. https://www.elaliberte.info/tag/developing-nations

Great article Lot's of information to Read...Great Man Keep Posting and update to People..Thanks showbox apk download

Cool stuff you have got and you keep update all of us. retail cleaning services

Excellent website you have here, so much cool information!.. best sports betting

Some truly wonderful work on behalf of the owner of this internet site , perfectly great articles . Sayings

Super-Duper site! I am Loving it!! Will come back again, Im taking your feed also, Thanks. 바둑이사이트

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. free samples by mail free shipping

It was wondering if I could use this write-up on my other website, I will link it back to your website though.Great Thanks. Smartphones

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches